These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 9838910

  • 1. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N, Aiba K, Fukuoka M, Akazawa S, Sakata Y, Furuse K, Kanamaru R, Kudoh S, Konishi T, Kurihara M, Niitani H, Furue H, Tsukagoshi S, Taguchi T, Yoshida S, Ota K, Kotake T, Wakui A.
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
    [Abstract] [Full Text] [Related]

  • 2. [A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer].
    Nishisho I, Kikkawa N, Ebata T, Osanai H, Ujiie S, Mitachi Y, Tsutsui M, Sawai K, Nishiguchi Y, Yasutake K, Wakasugi H, Wakui A.
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):81-91. PubMed ID: 10660737
    [Abstract] [Full Text] [Related]

  • 3. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ.
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [Abstract] [Full Text] [Related]

  • 4. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
    Vokes EE, Goh BC, Bertucci D, Vogelzang NJ, Mani S, Ratain MJ.
    Cancer; 1999 Aug 01; 86(3):528-32. PubMed ID: 10430263
    [Abstract] [Full Text] [Related]

  • 5. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T, Niitani H, Furue H, Tsukagoshi S, Kanamaru R, Hasegawa K, Akazawa S, Yoneda S, Tominaga T, Sasaki T.
    Gan To Kagaku Ryoho; 1995 Feb 01; 22(2):259-71. PubMed ID: 7857102
    [Abstract] [Full Text] [Related]

  • 6. ZD-9331 AstraZeneca.
    Niculescu-Duvaz I.
    Curr Opin Investig Drugs; 2000 Sep 01; 1(1):141-9. PubMed ID: 11249590
    [Abstract] [Full Text] [Related]

  • 7. [Phase I study of CI-898. CI-898 Study Group].
    Taguchi T, Tsukagoshi S, Furue H, Niitani H, Ohta K, Ariyoshi H, Hasegawa K, Majima H, Nakao I, Yasutomi M.
    Gan To Kagaku Ryoho; 1991 Aug 01; 18(10):1599-612. PubMed ID: 1831340
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
    Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S.
    Clin Cancer Res; 2005 Mar 01; 11(5):1884-9. PubMed ID: 15756014
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration.
    Jodrell DI, Bowman A, Rye R, Byrne B, Boddy A, Rafi I, Taylor GA, Johnston A, Clendeninn NJ.
    Br J Cancer; 1999 Feb 01; 79(5-6):915-20. PubMed ID: 10070890
    [Abstract] [Full Text] [Related]

  • 10. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
    Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR.
    J Clin Oncol; 1996 May 01; 14(5):1495-503. PubMed ID: 8622063
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 12. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y, Ohtsu A, Boku N, Miyata Y, Shimada Y, Doi T, Muro K, Muto M, Hamaguchi T, Mera K, Yano T, Tanigawara Y, Shirao K.
    Jpn J Clin Oncol; 2006 Apr 15; 36(4):218-23. PubMed ID: 16684860
    [Abstract] [Full Text] [Related]

  • 13. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
    Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML.
    Clin Cancer Res; 2008 Dec 01; 14(23):7947-55. PubMed ID: 19047127
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
    Sato A, Kurihara M, Horikoshi N, Aiba K, Kikkawa N, Shirouzu K, Mitachi Y, Sakata Y, Wakui A.
    Anticancer Drugs; 1999 Sep 01; 10(8):741-8. PubMed ID: 10573207
    [Abstract] [Full Text] [Related]

  • 15. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):139-47. PubMed ID: 16819636
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y.
    Cancer Chemother Pharmacol; 2006 Aug 01; 58(2):173-82. PubMed ID: 16308697
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
    Beutel G, Glen H, Schöffski P, Chick J, Gill S, Cassidy J, Twelves C.
    Clin Cancer Res; 2005 Aug 01; 11(15):5487-95. PubMed ID: 16061865
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kränzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queisser W.
    Clin Cancer Res; 1999 Apr 01; 5(4):753-9. PubMed ID: 10213209
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of ZD1694 in patients with advanced gastric cancer.
    Meropol NJ, Pazdur R, Vincent M, Willson JK, Kelsen DP, Douglass HO.
    Am J Clin Oncol; 1996 Dec 01; 19(6):628-30. PubMed ID: 8931686
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F, Avallone A, McLeod H, Cartenì G, De Vita F, Casaretti R, Morsman J, Blackie R, Budillon A, De Lucia L, Gravina A, Catalano G, Comella P, Comella G.
    Clin Cancer Res; 1999 Dec 01; 5(12):3948-55. PubMed ID: 10632324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.